Pegcetacoplan is the first complement component 3 (C3)–targeted therapy approved in the United States for adults with PNH [11] and in Europe for adults with PNH who are anemic after receiving a C5 inhibitor for ≥3 months [12]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.